Article
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Clinical lung cancer - 1 Nov 2014
Landi Lorenza, Tiseo Marcello, Chiari Rita, Ricciardi Serena, Rossi Elisa, Galetta Domenico, Novello Silvia, Milella Michele, D'Incecco Armida, Minuti Gabriele, Tibaldi Carmelo, Salvini Jessica, Facchinetti Francesco, Haspinger Eva Regina, Cortinovis Diego, Santo Antonio, Banna Giuseppe, Catino Annamaria, GiajLevra Matteo, Crinò Lucio, de Marinis Filippo, Cappuzzo Federico
Abstract excerpt
BACKGROUND: The purpose of this study was to evaluate the efficacy of afatinib in EGFR-mutant metastatic NSCLC patients with acquired resistance to erlotinib or gefitinib. MATERIALS AND METHODS: We retrospectively analyzed the outcome of patients with EGFR-mutant advanced NSCLC treated with afatinib after failure of chemotherapy and EGFR TKIs. RESULTS: A total of 96 individuals were included in the study....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.